Publicaciones en las que colabora con Jesús Devesa Múgica (18)

1993

  1. Glucocorticoids may inhibit growth hormone release by enhancing β-adrenergic responsiveness in hypothalamic somatostatin neurons

    Journal of Clinical Endocrinology and Metabolism, Vol. 76, Núm. 2, pp. 439-444

  2. Studies on α2-adrenergic modulation of hypothalamic somatostatin secretion in rats

    Life Sciences, Vol. 53, Núm. 8, pp. 665-668

1992

  1. Neuroendocrine control of growth hormone secretion in humans

    Trends in Endocrinology and Metabolism

1991

  1. Clonidine pretreatment modifies the growth hormone secretory pattern induced by shortterm continuous GRF infusion in normal man

    Clinical Endocrinology, Vol. 35, Núm. 2, pp. 129-135

  2. Evidence that α2-Adrenergic pathways play a major role in growth hormone (GH) neuroregulation: α2-Adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH Response to GH-Releasing Hormone, while α2-Adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men

    Journal of Clinical Endocrinology and Metabolism, Vol. 73, Núm. 2, pp. 251-256

  3. Growth hormone and aging

    Endocrinologia, Vol. 38, Núm. 8, pp. 254-260

  4. Role of central dopaminergic pathways in the neural control of growth hormone secretion in normal men: Studies with metoclopramide

    Neuroendocrinology, Vol. 53, Núm. 2, pp. 143-149

  5. The role of sexual steroids in the modulation of growth hormone (GH) secretion in humans

    Journal of Steroid Biochemistry and Molecular Biology, Vol. 40, Núm. 1-3, pp. 165-173

1990

  1. α2-adrenergic agonism enhances the growth hormone (gh) response to gh-releasing hormone through an inhibition of hypothalamic somatostatin release in normal men

    Journal of Clinical Endocrinology and Metabolism, Vol. 71, Núm. 6, pp. 1581-1588

1989

  1. Controversies in the GH response to GHRH in man

    Recent advances in basic and clinical neuroendocrinology: proceedings of the 4th Meeting of the European Neuroendocrine Association. ICS864

  2. Growth hormone (GH) responsiveness to GHRH in normal adults is not affected by short-term gonadal blockade

    Acta Endocrinologica, Vol. 120, Núm. 1, pp. 31-36

  3. REASONS FOR THE VARIABILITY IN GROWTH HORMONE (GH) RESPONSES TO GHRH CHALLENGE: THE ENDOGENOUS HYPOTHALAMIC‐SOMATOTROPH RHYTHM (HSR)

    Clinical Endocrinology, Vol. 30, Núm. 4, pp. 367-377

1988

  1. Adrenal androgen secretion and dopaminergic activity in Anorexia Nervosa

    Hormone and Metabolic Research, Vol. 20, Núm. 1, pp. 57-60

  2. Depending on the time of administration, dexamethasone potentiates or blocks growth hormone-releasing hormone-induced growth hormone release in man

    Neuroendocrinology, Vol. 47, Núm. 1, pp. 46-49

  3. Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary

    European Journal of Pharmacology, Vol. 151, Núm. 1, pp. 97-102

1987

  1. Adrenal cortex and type II polycystic ovary syndrome

    Gynecological Endocrinology, Vol. 1, Núm. 3, pp. 269-277

  2. GROWTH HORMONE AND PROLACTIN SECRETION AFTER GROWTH HORMONE‐RELEASING HORMONE ADMINISTRATION, IN ANOREXIA NERVOSA PATIENTS, NORMAL CONTROLS AND TAMOXIFEN‐PRETREATED VOLUNTEERS

    Clinical Endocrinology, Vol. 27, Núm. 5, pp. 517-523

  3. Morphological and functional stimulation of adrenal reticularis zone by dopaminergic blockade in dogs

    Journal of Steroid Biochemistry, Vol. 28, Núm. 5, pp. 465-470